Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency

(2022) Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency. JOURNAL OF CLINICAL IMMUNOLOGY. pp. 634-652. ISSN 0271-9142 1573-2592 J9 - J CLIN IMMUNOL

Full text not available from this repository.

Abstract

Purpose MALT1 deficiency is a combined immune deficiency characterized by recurrent infections, eczema, chronic diarrhea, and failure to thrive. Clinical and immunological characterizations of the disease have not been previously reported in large cohorts. We sought to determine the clinical, immunological, genetic features, and the natural history of MALT-1 deficiency. Methods The clinical findings and treatment outcomes were evaluated in nine new MALT1-deficient patients. Peripheral lymphocyte subset analyses, cytokine secretion, and proliferation assays were performed. We also analyzed ten previously reported patients to comprehensively evaluate genotype/phenotype correlation. Results The mean age of patients and disease onset were 33 +/- 17 and 1.6 +/- 0.7 months, respectively. The main clinical findings of the disease were recurrent infections (100), skin involvement (100), failure to thrive (100), oral lesions (67), chronic diarrhea (56), and autoimmunity (44). Eosinophilia and high IgE were observed in six (67) and two (22) patients, respectively. The majority of patients had normal T and NK cells, while eight (89) exhibited reduced B cells. Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications. One patient received hematopoietic stem cell transplantation (HSCT) and five patients died as a complication of life-threatening infections. Analyzing this cohort with reported patients revealed overall survival in 58 (11/19), which was higher in patients who underwent HSCT (P = 0.03). Conclusion This cohort provides the largest analysis for clinical and immunological features of MALT1 deficiency. HSCT should be offered as a curative therapeutic option for all patients at the early stage of life.

Item Type: Article
Keywords: Inborn errors of immunity primary immunodeficiency MALT1 combined immune deficiency immune dysregulation recurrent infections skin involvement failure to thrive hematopoietic stem cell transplantation NF-KAPPA-B T-CELL COMBINED IMMUNODEFICIENCY MUTATIONS ACTIVATION CARMA1 ROLES
Page Range: pp. 634-652
Journal or Publication Title: JOURNAL OF CLINICAL IMMUNOLOGY
Journal Index: ISI
Volume: 42
Number: 3
Identification Number: https://doi.org/10.1007/s10875-021-01191-4
ISSN: 0271-9142 1573-2592 J9 - J CLIN IMMUNOL
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/16280

Actions (login required)

View Item View Item